Andrew Dudum, Hims & Hers CEO
May 21, 2024 11:47 AM EDTUpdated May 21, 09:20 PM
Law
Health Tech

Hims’ push in­to com­pound­ed GLP-1 drugs risks scruti­ny from No­vo Nordisk

Ngai Yeung

Health Tech Reporter

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

The dig­i­tal health …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times